Systemic inflammation in chronic obstructive pulmonary disease and lung cancer: Common driver of pulmonary cachexia?

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 4, 2014, Pages 339-345

  Ceelen, Judith J M ^a   Langen, Ramon C J ^a   Schols, Annemie M W J ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cachexia; Chronic obstructive pulmonary disease; Lung cancer; Muscle; Orthotopic models; Systemic inflammation

Indexed keywords

AUTACOID; CYTOKINE; PROTEASOME; UBIQUITIN;

ADIPOSE TISSUE; ANIMAL; AUTOPHAGY; CACHEXIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLICATION; HUMAN; INFLAMMATION; LUNG TUMOR; LYSOSOME; METABOLISM; MOUSE; MUSCLE ATROPHY; NON SMALL CELL LUNG CANCER; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; AUTOPHAGY; CACHEXIA; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; LYSOSOMES; MICE; MUSCULAR ATROPHY; PROTEASOME ENDOPEPTIDASE COMPLEX; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; UBIQUITIN;

EID: 84919640477     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000088     Document Type: Review

References (58)

1. Gioulbasanis I, Patrikidou A, Kitikidou K, et al. Baseline plasma levels of interleukin-8 in stage IV nonsmall-cell lung cancer patients: relationship with nutritional status and prognosis. Nutr Cancer 2012; 64:41-47.
2. Gulen ST, Karadag F, Karul AB, et al. Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung 2012; 190:327-332.
3. Agustí A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One 2012; 7:e37483.
4. Broekhuizen R, Grimble RF, Howell WM, et al. Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1b -511 single nucleotide polymorphism. Am J Clin Nutr 2005; 82:1059-1064.
5. Eagan TM, Gabazza EC, D'Alessandro-Gabazza C, et al. TNF-alpha is associated with loss of lean body mass only in already cachectic COPD patients. Respir Res 2012; 13:48.
6. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with nonsmall-cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010; 91:1133S-1137S.
7. Schols AM. Nutrition as a metabolic modulator in COPD. Chest 2013; 144:1340-1345.
8. Rutten EP, Breyer MK, Spruit MA, et al. Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease. Clin Nutr 2010; 29:756-760.
9. van den Borst B, Gosker HR, Koster A, et al. The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. Am J Clin Nutr 2012; 96:516-526.
10. Langen RC, Gosker HR, Remels AH, Schols AM. Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease. Int J Biochem Cell Biol 2013; 45:2245-2256.
11. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 2011; 12:489-495.
12. Blum D, Stene GB, Solheim TS, et al. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model: A study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 2014; 25:1635-1642.
13. Op den Kamp CM, Langen RC, Snepvangers FJ, et al. Nuclear transcription factor kappa B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. Am J Clin Nutr 2013; 98:738-748.
14. Op den Kamp CM, Langen RC, Minnaard R, et al. Precachexia in patients with stages I-III nonsmall cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer 2012; 76:112-117.
15. MacNee W. Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease. Ann Med 2013; 45:291-300.
16. Rinaldi M, Maes K, De Vleeschauwer S, et al. Long-term nose-only cigarette smoke exposure induces emphysema and mild skeletal muscle dysfunction in mice. Dis Model Mech 2012; 5:333-341.
17. Gosker HR, Langen RCJ, Bracke KR, et al. Extrapulmonary manifestations of chronic obstructive pulmonary disease in a mouse model of chronic cigarette smoke exposure. Am J Respir Cell Mol Biol 2009; 40:710-716.
18. De Paepe B, Brusselle G, Maes T, et al. TNFa receptor genotype influences smoking-induced muscle-fibre-type shift and atrophy in mice. Acta Neuropathol 2008; 115:675-681.
19. Degens H, Swisher AK, Heijdra YF, et al. Apoptosis and Id2 expression in diaphragm and soleus muscle from the emphysematous hamster. Am J Physiol Regul Integr Comp Physiol 2007; 293:R135-R144.
20. Mador MJ, Mogri M, Lewis M, et al. Exercise capacity in hamsters with elastase-induced emphysema compared to normal controls. Respir Physiol Neurobiol 2010; 173:16-22.
21. Langen RCJ, Schols AMWJ, Kelders MCJM, et al. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol 2006; 35:689-696.
22. Langen RCJ, Haegens A, Vernooy JHJ, et al. NF-kB activation is required for the transition of pulmonary inflammation to muscle atrophy. Am J Respir Cell Mol Biol 2012; 47:288-297.
23. Files DC, D'Alessio FR, Johnston LF, et al. A critical role for muscle ring finger- 1 in acute lung injury-associated skeletal muscle wasting. Am J Respir Crit Care Med 2012; 185:825-834.
24. Vernooy JHJ, Reynaert N, Wolfs TGAM, et al. Rapid pulmonary expression of acute-phase reactants after local lipopolysaccharide exposure in mice is followed by an interleukin-6 mediated systemic acute-phase response. Exp Lung Res 2005; 31:855-871.
25. Kobayashi S, Fujinawa R, Ota F, et al. A single dose of lipopolysaccharide into mice with emphysema mimics human chronic obstructive pulmonary disease exacerbation as assessed by micro-computed tomography. Am J Respir Cell Mol Biol 2013; 49:971-977.
26. Bonetto A, Aydogdu T, Kunzevitzky N, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One 2011; 6:e22538.
27. Choi E, Carruthers K, Zhang L, et al. Concurrent muscle and bone deterioration in a murine model of cancer cachexia. Physiol Rep 2013; 1:e00144.
28. Puppa MJ, Gao S, Narsale AA, Carson JA. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia. FASEB J 2014; 28:998- 1009.
29. Chacon-Cabrera A, Fermoselle C, Urtreger AJ, et al. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness. J Cell Physiol 2014; 229:1660-1672.
30. Bassères DS, Ebbs A, Cogswell PC, Baldwin AS. IKK is a therapeutic target in KRAS-induced lung cancer with disrupted p53 activity. Genes Cancer 2014; 5:41-55.
31. Nakai M, Komiya K, Murata M, et al. Expression of pIX gene induced by transgene promoter: possible cause of host immune response in first-generation adenoviral vectors. Hum Gene Ther 2007; 18:925-936.
32. Penna F, Costamagna D, Pin F, et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am J Pathol 2013; 182:1367-1378.
33. Talbert EE, Metzger GA, He WA, Guttridge DC. Modeling human cancer cachexia in colon 26 tumor-bearing adult mice. J Cachexia Sarcopenia Muscle 2014. [Epub ahead of print].
34. He WA, Calore F, Londhe P, et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A 2014; 111:4525-4529.
35. He WA, Berardi E, Cardillo VM, et al. NF-kB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 2013; 123:4821-4835.
36. Sanchez AJ, Candau R, Bernardi H. FoxO transcription factors: Their roles in the maintenance of skeletal muscle homeostasis. Cell Mol Life Sci 2014; 71:1657-1671.
37. Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: Molecular basis and therapeutic potential. Int J Biochem Cell Biol 2013; 45:2333-2347.
38. Shimizu N, Yoshikawa N, Ito N, et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011; 13:170-182.
39. Cai D, Frantz JD, Tawa NE Jr, et al. IKKb/NF-kB activation causes severe muscle wasting in mice. Cell 2004; 119:285-298.
40. Haegens A, Schols AM, Gorissen SH, et al. NF-kappaB activation and polyubiquitin conjugation are required for pulmonary inflammation-induced diaphragm atrophy. Am J Physiol Lung Cell Mol Physiol 2012; 302:L103- L110.
41. Schakman O, Dehoux M, Bouchuari S, et al. Role of IGF-I and the TNFalpha/NF-kappaB pathway in the induction of muscle atrogenes by acute inflammation. Am J Physiol Endocrinol Metab 2012; 303:E729- E739.
42. Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012; 303:E410-E421.
43. Braun TP, Zhu X, Szumowski M, et al. Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis. J Exp Med 2011; 208:2449-2463.
44. Watson ML, Baehr LM, Reichardt HM, et al. A cell-autonomous role for the glucocorticoid receptor in skeletal muscle atrophy induced by systemic glucocorticoid exposure. Am J Physiol Endocrinol Metab 2012; 302: E1210-E1220.
45. Braun TP, Grossberg AJ, Krasnow SM, et al. Cancer- And endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle. FASEB J 2013; 27:3572-3582.
46. Lemire BB, Debigare R, Dube A, et al. MAPK signaling in the quadriceps of patients with chronic obstructive pulmonary disease. J Appl Physiol (1985) 2012; 113:159-166.
47. Fermoselle C, Rabinovich R, Ausín P, et al. Does oxidative stress modulate limb muscle atrophy in severe COPD patients? Eur Respir J 2012; 40:851- 862.
48. Doucet M, Russell AP, Léger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:261-269.
49. Natanek SA, Riddoch-Contreras J, Marsh GS, et al. MuRF-1 and atrogin-1 protein expression and quadriceps fiber size and muscle mass in stable patients with COPD. COPD 2013; 10:618-624.
50. Tardif N, Klaude M, Lundell L, et al. Autophagic-lysosomal pathway is the main proteolytic system modified in the skeletal muscle of esophageal cancer patients. Am J Clin Nutr 2013; 98:1485-1492.
51. Johns N, Hatakeyama S, Stephens NA, et al. Clinical classification of cancer cachexia: phenotypic correlates in human skeletal muscle. PLoS One 2014; 9:e83618.
52. Guo Y, Gosker HR, Schols AMWJ, et al. Autophagy in locomotor muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188:1313-1320.
53. Agustí A, Morlá M, Sauleda J, et al. NF-kB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax 2004; 59:483-487.
54. Mercken EM, Hageman GJ, Langen RC, et al. Decreased exercise-induced expression of nuclear factor-kb-regulated genes in muscle of patients with copd. Chest 2011; 139:337-346.
55. Plant PJ, Brooks D, Faughnan M, et al. Cellular markers of muscle atrophy in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2010; 42:461-471.
56. Vogiatzis I, Simoes DCM, Stratakos G, et al. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J 2010; 36:301-310.
57. van Hees H, Schellekens W-J, Linkels M, et al. Plasma from septic shock patients induces loss of muscle protein. Crit Care 2011; 15:R233.
58. Dingemans AM, Geelen J, Langen RC, Schols AM. Phase II drugs that are currently in development for the treatment of cachexia. Expert Opin Investig Drugs 2014. [Epub ahead of print].